HMGA1 has predictive value in response to chemotherapy in gastric cancer
(2022) In Current Oncology 29(1). p.56-67- Abstract
Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with... (More)
Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.
(Less)
- author
- Pádua, Diana
; Pinto, Débora Filipa
; Figueira, Paula
; Pereira, Carlos Filipe
LU
; Almeida, Raquel and Mesquita, Patrícia
- organization
- publishing date
- 2022-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chemotherapy, Gastric cancer, HMGA1, Predictive value, Prognosis
- in
- Current Oncology
- volume
- 29
- issue
- 1
- pages
- 12 pages
- publisher
- MDPI AG
- external identifiers
-
- pmid:35049679
- scopus:85121629926
- ISSN
- 1718-7729
- DOI
- 10.3390/curroncol29010005
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- id
- 6e7c09f0-6aa3-4657-a7ab-031d7926e429
- date added to LUP
- 2022-04-12 15:51:23
- date last changed
- 2025-02-11 00:06:49
@article{6e7c09f0-6aa3-4657-a7ab-031d7926e429, abstract = {{<p>Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.</p>}}, author = {{Pádua, Diana and Pinto, Débora Filipa and Figueira, Paula and Pereira, Carlos Filipe and Almeida, Raquel and Mesquita, Patrícia}}, issn = {{1718-7729}}, keywords = {{Chemotherapy; Gastric cancer; HMGA1; Predictive value; Prognosis}}, language = {{eng}}, number = {{1}}, pages = {{56--67}}, publisher = {{MDPI AG}}, series = {{Current Oncology}}, title = {{HMGA1 has predictive value in response to chemotherapy in gastric cancer}}, url = {{http://dx.doi.org/10.3390/curroncol29010005}}, doi = {{10.3390/curroncol29010005}}, volume = {{29}}, year = {{2022}}, }